Ambrx Biopharma Inc. AMAM NYSE

Ambrx Biopharma Inc. (AMAM) reported total assets of $271.5M and total liabilities of $29.1M for quarter ending 2023-09-30, resulting in total equity of $242.4M.

The company held $225.26M in cash and short-term investments. Total debt stood at $10.52M, with net debt of $-214.74M. The Debt-to-Equity (D/E) ratio was 0.04 (conservative).

Current ratio is 12.8, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (58/100) — Total assets $271.5M and equity $242.4M support the company's competitive scale

Overall SharesGrow Score: 28/100 with 0/7 criteria passed.